Skip to main content
Year archive

Egetis Therapeutics — 2022 filings

All 31 regulatory filings released by Egetis Therapeutics (EGTX) in 2022, sourced directly from the official regulator.

31 Filings
2022 Period
2022 filings (31)
Filing Released Lang
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-08 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-08 English
Egetis valberedning utsedd inför årsstämman 2023
Board/Management Information
2022-10-25 Swedish
Egetis presents Nomination Committee for the 2023 Annual General Meeting
AGM Information
2022-10-25 English
Interim / Quarterly Report 2022
Interim / Quarterly Report H2 2022
2022-08-19 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report H2 2022
2022-08-19 English
Change in the number of shares and votes in Egetis Therapeutics
Declaration of Voting Results & Voting Rights Announcements
2022-05-31 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Report Publication Announcement
2022-05-31 Swedish
Kommuniké från Egetis Therapeutics årsstämma 2022
AGM Information
2022-05-30 Swedish
Bulletin from Egetis Therapeutics’ Annual General Meeting 2022
AGM Information
2022-05-30 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-05-20 English
Egetis Therapeutics raises approximately SEK 180 million through an oversubscribed rights issue
Capital/Financing Update
2022-05-19 English
Egetis Therapeutics tillförs cirka 180 MSEK genom övertecknad företrädesemission
Capital/Financing Update
2022-05-19 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-05-18 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-05-17 English
Egetis Therapeutics publishes prospectus relating to the Rights Issue
Capital/Financing Update
2022-04-28 English
Egetis Therapeutics offentliggör prospekt avseende företrädesemissionen
Capital/Financing Update
2022-04-28 Swedish
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB
Proxy Solicitation & Information Statement
2022-04-28 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-26 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-26 English
Annual Report 2021
Annual Report FY 2021
2022-04-20 Swedish
Kommuniké från extra bolagsstämma i Egetis Therapeutics AB samt offentliggörande av tidsplan i samband med företrädesemissionen
Capital/Financing Update
2022-04-13 Swedish
Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue
AGM Information
2022-04-13 English
NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS
AGM Information
2022-03-21 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I EGETIS THERAPEUTICS
AGM Information
2022-03-21 Swedish
Egetis Therapeutics beslutar om en fullt garanterad företrädesemission om cirka 180 MSEK
Share Issue/Capital Change
2022-03-21 Swedish
Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million
Capital/Financing Update
2022-03-21 English
Audit Report / Information 2021
Audit Report / Information FY 2021
2022-02-17 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report FY 2021
2022-02-17 English
Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US
Regulatory Filings
2022-01-18 English
Egetis drar slutsatsen att en behandlingseffekt på T3-nivåer hos patienter med MCT8-brist kan utgöra grund för marknadsgodkännande av Emcitate® i USA
Regulatory Filings
2022-01-18 Swedish